Summary
We are delighted to share that the ICM - Institut du Cancer de Montpellier was authorized by the French Data Protection Authority (CNIL) to conduct APAD-ECO study.
The CNIL granted authorization to conduct a medico-economic study on the effects of physical activity in women treated for breast cancer on April, 19th. This groundbreaking study involves combining data from two clinical trials with that of the Caisse nationale de l’Assurance Maladie, covering the period from 2009 to 2022.
The study aims to assess the long-term impacts of physical activity in patients who have undergone treatment for breast cancer.
We are proud to have contributed to this project by providing the ICM - Institut du Cancer de Montpellier with a compliant Data Protection Impact Assessment (DPIA), a crucial step in obtaining CNIL approval.
Sign up for our newsletter
We like to keep our readers up to date on complex regulatory issues, the latest industry trends and updated guidelines to help you to solve a problem or make an informed decision.
Data Protection Strategies for Phase III Clinical Trials
Phase III clinical trials require strict compliance with privacy and data protection laws across multiple jurisdictions, including GDPR obligations, local authorizations, and ethics committee oversight. The article outlines practical strategies such as the “funnel approach” to harmonize global frameworks, manage cross-border transfers, appoint Data Protection Officers, and ensure proper informed consent documentation. It also emphasizes the need for local representatives, jurisdiction-specific formalities, and standardized templates to maintain compliance and avoid delays in global studies.
Addressing the Data Protection and Ethical Challenges posed by AI in Health – Part 2
Our latest analysis: U.S. vs EU—AI regulation shaping healthcare’s future.
Interview Paul Chilo Director of Governance, Risk & Compliance at SOPHiA GENETICS - SOPHiA UNITY
